These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 21481325)

  • 1. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N
    Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
    Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
    J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
    Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA; Stensson A; Schön K; Lycke N
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
    Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
    Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y; Larsson L; Mattsson J; Lycke N; Xiang Z
    J Immunol; 2010 Sep; 185(5):2935-41. PubMed ID: 20675596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
    Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
    Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine.
    Quan Le M; Ye L; Bernasconi V; Carpentier R; Fasquelle F; Lycke N; Staeheli P; Betbeder D
    Int J Pharm; 2020 May; 582():119348. PubMed ID: 32325240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC; Ekman L; Löwenadler B; Lycke NY
    J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.